Inventor · disambiguated record
David Stover
Also filed as: STOVER DAVID · STOVER DAVID R · STOVER DAVID RAYMOND
16 granted patents·13 pending applications·294 citations·filing 1998–2025
92Inventor score
Top patents by PatentIndex Score
29 records- 0196US6258812B1Phthalazines with angiogenesis inhibiting activityNOVARTIS AG·Filed 1998·Granted Jul 10, 2001·206 cites·30 claims
- 0292US11896646B2Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2022·Granted Feb 13, 2024·1 cites·16 claims
- 0391US11136353B2Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereofQWIXEL THERAPEUTICS LLC·Filed 2020·Granted Oct 5, 2021·3 cites·31 claims
- 0489US12162958B2Fusion protein composition(s) comprising masked type i interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereofQWIXEL THERAPEUTICS LLC·Filed 2023·Granted Dec 10, 2024·1 cites·29 claims
- 0588US8101727B2Compositions and methods of use for antibodies of c-MetSTOVER DAVID RAYMOND·Filed 2007·Granted Jan 24, 2012·33 cites·31 claims
- 0687US11679141B2Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2021·Granted Jun 20, 2023·1 cites·9 claims
- 0787US6710047B2Phthalazines with angiogenesis inhibiting activityNOVARTIS AG·Filed 2003·Granted Mar 23, 2004·25 cites·4 claims
- 0886US11744874B2Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2020·Granted Sep 5, 2023·1 cites·9 claims
- 0985US12311010B2Formulated and/or co-formulated liposome compositions containing toll-like receptor(“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2023·Granted May 27, 2025·0 cites·14 claims
- 1085US11801304B2Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2021·Granted Oct 31, 2023·1 cites·14 claims
- 1185US2024123028A1Formulated and/or Co-Formulated Liposome Compositions Containing Toll-Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof CNAMMI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1283US6514974B2Pyrido-, pyrimido-, pyridazo- and pyrazo- pyridazines having angiogenesis inhibiting activityNOVARTIS AG·Filed 2001·Granted Feb 4, 2003·15 cites·8 claims
- 1382US2023277621A1Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1479US12059470B2Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2023·Granted Aug 13, 2024·0 cites·18 claims
- 1578US9120855B2Biologic compounds directed against death receptor 5CROMIE KAREN·Filed 2011·Granted Sep 1, 2015·7 cites·17 claims
- 1678US2025032620A1Formulated and/or Co-Formulated Nanocarrier Compositions Containing TFGß Antagonist Prodrugs Useful in the Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1776US2024366772A1Formulated and/or Co-Formulated Liposome Compositions Containing PD-1 Antagonist Prodrugs Useful in the Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1875US2025313531A1Formulated and/or Co-Formulated Liposome Compositions Containing IDO Antagonist Prodrugs Useful in the Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1975US2025177484A1Formulated and/or Co-Formulated Liposome Compositions Containing Toll-Like Receptor (TLR) Agonist Prodrugs Useful in the Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2075US2024050575A1Formulated and/or co-formulated liposome compositions containg TGFb antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2173US11833209B2Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2021·Granted Dec 5, 2023·0 cites·15 claims
- 2272US11795198B2Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereofQWIXEL THERAPEUTICS LLC·Filed 2021·Granted Oct 24, 2023·0 cites·27 claims
- 2368US12286403B2Formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2020·Granted Apr 29, 2025·0 cites·19 claims
- 2462US2024108732A1Formulated and/or Co-Formulated Lipid Nanocarriers Compositions Containing Toll-Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2559US2025325634A1Fusion Protein Composition(s) Comprising Masked Type I Interferons (IFNa and IFNb) For Use in the Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2658US2023226031A1Formulated and/or Co-Formulated Liposome Compositions Containing Immunogenic Cell Death (ICD) Inducing Prodrugs Useful In The Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2757US2022401451A1Formulated and/or co-formulated compositions containing A2aR antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2849US2014134173A1Composition and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or bothBRAENDLE EDGAR·Filed 2013·Application pending·0 cites
- 2941US2012052070A1Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or bothBRAENDLE EDGAR·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Stover files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →